KRT-232-111
Research type
Research Study
Full title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
IRAS ID
289212
Contact name
Dima El-Sharkawi
Contact email
Sponsor organisation
Kartos Therapeutics Inc.
Eudract number
2020-002464-31
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 5 months, 0 days
Research summary
Participants diagnosed with Diffuse Large B-Cell Lypmphoma (DLBCL) or Choronic Lymphocytic Leukemia (CLL) are being invited to participate in this study as their previous treatments have failed or have not been effective enough.
This study will test an investigational product (IP) called KRT-232 that has not been approved for the potential treatment of DLBCL or CLL.
KRT-232 is a tablet that is taken by mouth with water. KRT-232 will be taken in combination with another approved medicine for CLL called acalabrutinib (Calquence).
Acalabrutinib is not approved for the treatment of DLBCL. The purpose of this study is to determine an appropriate dose of KRT-232 in combination with acalabrutinib for treatment of DLBCL or CLL.REC name
South Central - Oxford A Research Ethics Committee
REC reference
21/SC/0059
Date of REC Opinion
28 Jun 2021
REC opinion
Further Information Favourable Opinion